お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書は、ペプチドCDMOの世界市場、容量、生産量、収益、価格の概要を紹介します。2020~2024年の歴史的な市場収益/売上データ、2025年の予想、および2031年までのCAGRの予測を含む世界市場動向の分析。本レポートはメーカー、地域、製品の種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、製品タイプとアプリケーション/端末業界別にペプチドCDMO市場を分類しています。
本レポートでは世界のペプチドCDMO市場の主な参加者として、企業概要、販売数量、収益、価格、粗利益率、ポートフォリオ、地理的位置、重要な発展を次のパラメータに基づいて紹介します。本研究に含まれる主な企業は：Bachem、PolyPeptide、CordenPharma、AmbioPharm、USV Peptides、Thermofischer、Bio Basic、JPT、Genscript、Xinbang Pharma、ScinoPharm、SN Biopharm、CBL、Piramal Pharma、CPC Scientific

レポートはペプチドCDMOの主要生産者を調査し、主要地域や国の消費状況も提供します。ペプチドCDMOの今後の市場の可能性のハイライト、およびこの市場をさまざまなセグメントおよびサブセグメントに予測するための主要な地域/国の焦点。アメリカとカナダ、中国、アジア、ヨーロッパ、中東、アフリカ、ラテンアメリカ、およびその他の国の国別データと市場価値分析。

2020年から2031年までのタイプ別および用途別、売上高、収益、価格別のセグメントデータを分析します。
タイプ別市場セグメント：
    APIs and Intermediates
    FDF

用途別の市場セグメント：
    Commercial
    Academic Research
    Other

本レポートの詳細内容
本レポートは、世界のペプチドCDMO市場の現状と将来展望を包括的に分析し、グローバルの主要地域における開発動向の綿密な調査を通じて、読者に包括的な市場分析を提示するものであります。市場の全体像を把握するために、プレイヤー、地域、製品タイプ、最終産業を網羅した多角的な分析を提供しています。さらに、世界市場のトッププレイヤーを特定し、プロファイルを作成するとともに、製品タイプや用途/最終産業に基づいてペプチドCDMO市場を細分化しています。この分類と応用により、市場の構造とダイナミクスをより深く理解することができ、情報に基づいた意思決定と戦略立案が可能になります。
一. 生産面では、2020年から2025年まで、そして2031年までの予測として、メーカー別、地域別（地域レベル、国レベル）のペプチドCDMO生産量、成長率、市場シェアを調査している。

二. 消費面では、ペプチドCDMOの売上高を地域別（地域レベル・国レベル）、企業別、種類別、用途別に焦点を当てています。2020年から2025年まで、2031年までの予測。

三.主要メーカーのペプチドCDMO売上高、収益、市場シェア、業界ランキング、2020年から2025年までのデータに焦点を当てています。世界のペプチドCDMO市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。

四.本ペプチドCDMOのレポートでは関係者が市場の競争状況を包括的に理解し、事業戦略や市場戦略を的確に立てるのに役立つ洞察を提供することを目的としています。 売上高、成長動向、生産技術、用途、エンドユーザー産業の市場規模に関する詳細な評価と予測を提供し、意思決定者に強力なデータサポートを提供します。

章の概要
第1章：ペプチドCDMOのレポート範囲、各市場セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメントのエグゼクティブサマリー（タイプ別およびアプリケーション別など）を紹介します。市場の現状と、短期から中期、および長期的な進化の可能性を高度に見ることができます。（2020～2031）
第2章： ペプチドCDMOの世界と主要生産者（地域／国）の生産／アウトプット。各生産者の生産量と今後6年間の発展可能性を定量的に分析しています。（2020～2031）
第3章：世界、地域、国レベルにおけるペプチドCDMOの売上（消費）、収益。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界の各国の市場発展、将来の発展の見通し、市場空間を紹介します。（2020～2031）
第4章ペプチドCDMOメーカーの競争状況、価格、売上高、収益、市場シェアと業界ランキング、最新の開発計画、合併、買収情報などの詳細分析。（2020～2025）
第5章：ペプチドCDMOの各市場セグメントの売上高、収益、平均価格、および開発可能性をカバーした種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2020～2031）
第6章：アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの売上高、収益、平均価格、発展の可能性をカバーし、読者が異なる下流市場でのブルーオーシャン市場を見つけるのに役立ちます。（2020～2031）
第7章：北米（米国・カナダ）：タイプ別、用途別、国別、セグメント別の売上高、収益。（2020～2031）
第8章：ヨーロッパ：タイプ別、用途別、国別、セグメント別の売上高と収益。（2020～2031）
第9章：中国：タイプ別、アプリケーション別、セグメント別の売上高、収益。（2020～2031）
第10章：アジア（中国を除く）：タイプ別、用途別、地域別、セグメント別の売上高、収益。（2020～2031）
第11章：中東、アフリカ、中南米：タイプ別、用途別、国別、セグメント別の売上高、収益。（2020～2031）
第12章：ペプチドCDMOの主要メーカーの概要を提供し、製品の説明と仕様、ペプチドCDMOの売上高、収益、価格、粗利益率、最近の発展など、市場の主要企業の基本的な状況を詳細に紹介します。（2020～2025）
第13章：産業チェーン、販売チャネル、主要原材料、販売代理店および顧客の分析。
第14章：ペプチドCDMOの市場動態、市場の最新の動向、市場の推進要因と制約要因、業界内のメーカーが直面する課題とリスク、業界内の関連政策の分析を紹介します。
第15章：レポートの要点と結論。

Valued at US$ 4805 million in 2024, the global Peptide CDMO market is forecast to reach US$ 11080 million by 2030, at a CAGR of 15.0% during the forecast period.
Peptides are synthesized by coupling the carboxyl group of one amino acid to the amino group of another amino acid molecule. Due to the possibility of unintended reactions, protecting groups are common necessary. Chemical peptide synthesis most commonly starts at the carboxyl end of the peptide, and thus progress toward the amino-terminus. This is the opposite direction of protein biosynthesis. A contract development and manufacturing company (CDMO) is a company within the pharmaceutical industry that provides drug development and manufacturing services. Pharmaceutical companies partner with CDMOs as a way to outsource drug development and drug manufacturing. CDMO peptides production via contract peptide manufacturing is to optimize process development and achieve highly efficient conversion at every amino acid coupling to produce a high-purity crude synthetic custom peptide and minimize the demands on downstream processing.
The Peptide CDMO (Contract Development and Manufacturing Organization) market is driven by the increasing demand for peptide-based therapeutics. Peptides are gaining significant traction in the pharmaceutical industry due to their high specificity, targeted action, and fewer side effects compared to traditional small-molecule drugs. As a result, there is growing interest in developing and manufacturing peptides for a wide range of indications, including oncology, diabetes, cardiovascular diseases, and neurological disorders. This shift is coupled with the rise in personalized medicine, where peptides are seen as promising candidates for tailored therapies. Peptide CDMOs are playing a crucial role by providing specialized services like synthesis, purification, and formulation, enabling pharmaceutical companies to bring peptide-based drugs to market faster and more efficiently. Additionally, advancements in peptide synthesis technologies and the increasing outsourcing trend by biopharmaceutical companies are fueling growth in this sector.
Despite the positive growth drivers, the Peptide CDMO market faces several challenges. One of the main hurdles is the complexity involved in peptide synthesis and manufacturing, particularly for large-scale production. Peptides are often fragile and prone to degradation, requiring strict control over production processes, which can be both time-consuming and costly. Additionally, the high costs of peptide synthesis, purification, and formulation pose significant barriers to entry for smaller players, limiting competition and innovation in the market. Furthermore, regulatory challenges are a concern, as peptides often face more stringent requirements during the clinical development and commercialization stages compared to traditional small-molecule drugs. These challenges can result in delays in drug development and increased production costs, which could ultimately impact the profitability of peptide CDMOs.
Global key peptide CDMO producers include Bachem, PolyPeptide, CordenPharma, and others. The top five manufacturers together account for 40% of the market share, with the largest manufacturer being Bachem with 17%. At the sales level, North America is the largest sales market with a market share of over 50%, followed by Europe and China with 33% and 9% respectively. 
Report Includes
This report presents an overview of global market for Peptide CDMO market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Peptide CDMO, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Peptide CDMO, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Peptide CDMO revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Peptide CDMO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Peptide CDMO revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Bachem, PolyPeptide, CordenPharma, AmbioPharm, USV Peptides, Thermofischer, Bio Basic, JPT, Genscript, Xinbang Pharma, etc.

Market Segmentation
By Company
    Bachem
    PolyPeptide
    CordenPharma
    AmbioPharm
    USV Peptides
    Thermofischer
    Bio Basic
    JPT
    Genscript
    Xinbang Pharma
    ScinoPharm
    SN Biopharm
    CBL
    Piramal Pharma
    CPC Scientific

Segment by Type
    APIs and Intermediates
    FDF

Segment by Application
    Commercial
    Academic Research
    Other

By Region
    North America
        United States
        Canada
    Asia-Pacific
        China
        Japan
        South Korea
        Southeast Asia
        India
        Australia
        Rest of Asia
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
        Nordic Countries
        Rest of Europe
    Latin America
        Mexico
        Brazil
        Rest of South America
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE
        Rest of MEA

Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Peptide CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Peptide CDMO companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Peptide CDMO revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

List of Tables
 Table 1. Global Peptide CDMO Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of APIs and Intermediates
 Table 3. Key Players of FDF
 Table 4. Global Peptide CDMO Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 5. Global Peptide CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Market Size by Region (2020-2031) & (US$ Million)
 Table 7. Global Peptide CDMO Market Share by Region (2020-2031)
 Table 8. Market Trends
 Table 9. Market Drivers
 Table 10. Market Challenges
 Table 11. Market Restraints
 Table 12. Global Peptide CDMO Revenue by Players (2020-2025) & (US$ Million)
 Table 13. Global Peptide CDMO Market Share by Players (2020-2025)
 Table 14. Global Top Peptide CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide CDMO as of 2024)
 Table 15. Global Peptide CDMO Industry Ranking 2023 VS 2024
 Table 16. Global 5 Largest Players Market Share by Peptide CDMO Revenue (CR5 and HHI) & (2020-2025)
 Table 17. Global Key Players of Peptide CDMO, Headquarters and Area Served
 Table 18. Global Key Players of Peptide CDMO, Product and Application
 Table 19. Global Key Players of Peptide CDMO, Date of Enter into This Industry
 Table 20. Mergers & Acquisitions, Expansion Plans
 Table 21. Global Market Size by Type (2020-2025) & (US$ Million)
 Table 22. Global Peptide CDMO Revenue Market Share by Type (2020-2025)
 Table 23. Global Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 24. Global Peptide CDMO Revenue Market Share by Type (2026-2031)
 Table 25. Global Market Size by Application (2020-2025) & (US$ Million)
 Table 26. Global Peptide CDMO Revenue Market Share by Application (2020-2025)
 Table 27. Global Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 28. Global Peptide CDMO Revenue Market Share by Application (2026-2031)
 Table 29. North America Market Size by Type (2020-2031) & (US$ Million)
 Table 30. North America Market Size by Application (2020-2031) & (US$ Million)
 Table 31. North America Peptide CDMO Growth Rate (CAGR) by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 32. North America Market Size by Country (2020-2031) & (US$ Million)
 Table 33. Europe Market Size by Type (2020-2031) & (US$ Million)
 Table 34. Europe Market Size by Application (2020-2031) & (US$ Million)
 Table 35. Europe Peptide CDMO Growth Rate (CAGR) by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 36. Europe Market Size by Country (2020-2025) & (US$ Million)
 Table 37. China Market Size by Type (2020-2031) & (US$ Million)
 Table 38. China Market Size by Application (2020-2031) & (US$ Million)
 Table 39. Asia Market Size by Type (2020-2031) & (US$ Million)
 Table 40. Asia Market Size by Application (2020-2025) & (US$ Million)
 Table 41. Asia Peptide CDMO Growth Rate (CAGR) by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 42. Asia Market Size by Region (2020-2031) & (US$ Million)
 Table 43. Middle East, Africa, and Latin America Market Size by Type (2020-2031) & (US$ Million)
 Table 44. Middle East, Africa, and Latin America Market Size by Application (2020-2031) & (US$ Million)
 Table 45. Middle East, Africa, and Latin America Peptide CDMO Growth Rate (CAGR) by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 46. Middle East, Africa, and Latin America Market Size by Country (2020-2031) & (US$ Million)
 Table 47. Bachem Company Details
 Table 48. Bachem Business Overview
 Table 49. Bachem Peptide CDMO Product
 Table 50. Bachem Revenue (2020-2025) & (US$ Million)
 Table 51. Bachem Recent Development
 Table 52. PolyPeptide Company Details
 Table 53. PolyPeptide Business Overview
 Table 54. PolyPeptide Peptide CDMO Product
 Table 55. PolyPeptide Revenue (2020-2025) & (US$ Million)
 Table 56. PolyPeptide Recent Development
 Table 57. CordenPharma Company Details
 Table 58. CordenPharma Business Overview
 Table 59. CordenPharma Peptide CDMO Product
 Table 60. CordenPharma Revenue (2020-2025) & (US$ Million)
 Table 61. CordenPharma Recent Development
 Table 62. AmbioPharm Company Details
 Table 63. AmbioPharm Business Overview
 Table 64. AmbioPharm Peptide CDMO Product
 Table 65. AmbioPharm Revenue (2020-2025) & (US$ Million)
 Table 66. AmbioPharm Recent Development
 Table 67. USV Peptides Company Details
 Table 68. USV Peptides Business Overview
 Table 69. USV Peptides Peptide CDMO Product
 Table 70. USV Peptides Revenue (2020-2025) & (US$ Million)
 Table 71. USV Peptides Recent Development
 Table 72. Thermofischer Company Details
 Table 73. Thermofischer Business Overview
 Table 74. Thermofischer Peptide CDMO Product
 Table 75. Thermofischer Revenue (2020-2025) & (US$ Million)
 Table 76. Thermofischer Recent Development
 Table 77. Bio Basic Company Details
 Table 78. Bio Basic Business Overview
 Table 79. Bio Basic Peptide CDMO Product
 Table 80. Bio Basic Revenue (2020-2025) & (US$ Million)
 Table 81. Bio Basic Recent Development
 Table 82. JPT Company Details
 Table 83. JPT Business Overview
 Table 84. JPT Peptide CDMO Product
 Table 85. JPT Revenue (2020-2025) & (US$ Million)
 Table 86. JPT Recent Development
 Table 87. Genscript Company Details
 Table 88. Genscript Business Overview
 Table 89. Genscript Peptide CDMO Product
 Table 90. Genscript Revenue (2020-2025) & (US$ Million)
 Table 91. Genscript Recent Development
 Table 92. Xinbang Pharma Company Details
 Table 93. Xinbang Pharma Business Overview
 Table 94. Xinbang Pharma Peptide CDMO Product
 Table 95. Xinbang Pharma Revenue (2020-2025) & (US$ Million)
 Table 96. Xinbang Pharma Recent Development
 Table 97. ScinoPharm Company Details
 Table 98. ScinoPharm Business Overview
 Table 99. ScinoPharm Peptide CDMO Product
 Table 100. ScinoPharm Revenue (2020-2025) & (US$ Million)
 Table 101. ScinoPharm Recent Development
 Table 102. SN Biopharm Company Details
 Table 103. SN Biopharm Business Overview
 Table 104. SN Biopharm Peptide CDMO Product
 Table 105. SN Biopharm Revenue (2020-2025) & (US$ Million)
 Table 106. SN Biopharm Recent Development
 Table 107. CBL Company Details
 Table 108. CBL Business Overview
 Table 109. CBL Peptide CDMO Product
 Table 110. CBL Revenue (2020-2025) & (US$ Million)
 Table 111. CBL Recent Development
 Table 112. Piramal Pharma Company Details
 Table 113. Piramal Pharma Business Overview
 Table 114. Piramal Pharma Peptide CDMO Product
 Table 115. Piramal Pharma Revenue (2020-2025) & (US$ Million)
 Table 116. Piramal Pharma Recent Development
 Table 117. CPC Scientific Company Details
 Table 118. CPC Scientific Business Overview
 Table 119. CPC Scientific Peptide CDMO Product
 Table 120. CPC Scientific Revenue (2020-2025) & (US$ Million)
 Table 121. CPC Scientific Recent Development
 Table 122. Research Programs/Design for This Report
 Table 123. Key Data Information from Secondary Sources
 Table 124. Key Data Information from Primary Sources


List of Figures
 Figure 1. Global Peptide CDMO Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 2. Global Peptide CDMO Market Share by Type: 2024 VS 2031
 Figure 3. APIs and Intermediates Features
 Figure 4. FDF Features
 Figure 5. Global Peptide CDMO Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 6. Global Peptide CDMO Market Share by Application: 2024 VS 2031
 Figure 7. Commercial Case Studies
 Figure 8. Academic Research Case Studies
 Figure 9. Other Case Studies
 Figure 10. Peptide CDMO Report Years Considered
 Figure 11. Global Peptide CDMO Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 12. Global Peptide CDMO Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 13. Global Peptide CDMO Market Share by Region: 2024 VS 2031
 Figure 14. Global Peptide CDMO Market Share by Players in 2024
 Figure 15. Global Top Peptide CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide CDMO as of 2024)
 Figure 16. The Top 10 and 5 Players Market Share by Peptide CDMO Revenue in 2024
 Figure 17. North America Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 18. North America Peptide CDMO Market Share by Type (2020-2031)
 Figure 19. North America Peptide CDMO Market Share by Application (2020-2031)
 Figure 20. North America Peptide CDMO Market Share by Country (2020-2031)
 Figure 21. United States Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Canada Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Europe Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Europe Peptide CDMO Market Share by Type (2020-2031)
 Figure 25. Europe Peptide CDMO Market Share by Application (2020-2031)
 Figure 26. Europe Peptide CDMO Market Share by Country (2020-2031)
 Figure 27. Germany Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. France Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. U.K. Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Italy Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Russia Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Nordic Countries Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. China Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. China Peptide CDMO Market Share by Type (2020-2031)
 Figure 35. China Peptide CDMO Market Share by Application (2020-2031)
 Figure 36. Asia Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Asia Peptide CDMO Market Share by Type (2020-2031)
 Figure 38. Asia Peptide CDMO Market Share by Application (2020-2031)
 Figure 39. Asia Peptide CDMO Market Share by Region (2020-2031)
 Figure 40. Japan Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. South Korea Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. China Taiwan Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Southeast Asia Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. India Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Australia Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Middle East, Africa, and Latin America Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Middle East, Africa, and Latin America Peptide CDMO Market Share by Type (2020-2031)
 Figure 48. Middle East, Africa, and Latin America Peptide CDMO Market Share by Application (2020-2031)
 Figure 49. Middle East, Africa, and Latin America Peptide CDMO Market Share by Country (2020-2031)
 Figure 50. Brazil Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 51. Mexico Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 52. Turkey Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 53. Saudi Arabia Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 54. Israel Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 55. GCC Countries Peptide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 56. Bachem Revenue Growth Rate in Peptide CDMO Business (2020-2025)
 Figure 57. PolyPeptide Revenue Growth Rate in Peptide CDMO Business (2020-2025)
 Figure 58. CordenPharma Revenue Growth Rate in Peptide CDMO Business (2020-2025)
 Figure 59. AmbioPharm Revenue Growth Rate in Peptide CDMO Business (2020-2025)
 Figure 60. USV Peptides Revenue Growth Rate in Peptide CDMO Business (2020-2025)
 Figure 61. Thermofischer Revenue Growth Rate in Peptide CDMO Business (2020-2025)
 Figure 62. Bio Basic Revenue Growth Rate in Peptide CDMO Business (2020-2025)
 Figure 63. JPT Revenue Growth Rate in Peptide CDMO Business (2020-2025)
 Figure 64. Genscript Revenue Growth Rate in Peptide CDMO Business (2020-2025)
 Figure 65. Xinbang Pharma Revenue Growth Rate in Peptide CDMO Business (2020-2025)
 Figure 66. ScinoPharm Revenue Growth Rate in Peptide CDMO Business (2020-2025)
 Figure 67. SN Biopharm Revenue Growth Rate in Peptide CDMO Business (2020-2025)
 Figure 68. CBL Revenue Growth Rate in Peptide CDMO Business (2020-2025)
 Figure 69. Piramal Pharma Revenue Growth Rate in Peptide CDMO Business (2020-2025)
 Figure 70. CPC Scientific Revenue Growth Rate in Peptide CDMO Business (2020-2025)
 Figure 71. Bottom-up and Top-down Approaches for This Report
 Figure 72. Data Triangulation
 Figure 73. Key Executives Interviewed